265 related articles for article (PubMed ID: 27341108)
1. Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.
Bialek JK; Dunay GA; Voges M; Schäfer C; Spohn M; Stucka R; Hauber J; Lange UC
PLoS One; 2016; 11(6):e0158294. PubMed ID: 27341108
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
3. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
[TBL] [Abstract][Full Text] [Related]
4. Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9.
Olson A; Basukala B; Lee S; Gagne M; Wong WW; Henderson AJ
Viruses; 2020 Oct; 12(10):. PubMed ID: 33053801
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs.
Zhang Y; Yin C; Zhang T; Li F; Yang W; Kaminski R; Fagan PR; Putatunda R; Young WB; Khalili K; Hu W
Sci Rep; 2015 Nov; 5():16277. PubMed ID: 26538064
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
[TBL] [Abstract][Full Text] [Related]
7. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
8. Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line.
Liu Y; Jeeninga RE; Klaver B; Berkhout B; Das AT
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960730
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-mediated Activation of Latent HIV-1 Expression.
Limsirichai P; Gaj T; Schaffer DV
Mol Ther; 2016 Mar; 24(3):499-507. PubMed ID: 26607397
[TBL] [Abstract][Full Text] [Related]
10. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing.
Kaminski R; Chen Y; Fischer T; Tedaldi E; Napoli A; Zhang Y; Karn J; Hu W; Khalili K
Sci Rep; 2016 Mar; 6():22555. PubMed ID: 26939770
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus.
Ebina H; Misawa N; Kanemura Y; Koyanagi Y
Sci Rep; 2013; 3():2510. PubMed ID: 23974631
[TBL] [Abstract][Full Text] [Related]
12. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
[TBL] [Abstract][Full Text] [Related]
14. Multiplexed Simian Immunodeficiency Virus-Specific Paired RNA-Guided Cas9 Nickases Inactivate Proviral DNA.
Smith LM; Ladner JT; Hodara VL; Parodi LM; Harris RA; Callery JE; Lai Z; Zou Y; Raveedran M; Rogers J; Giavedoni LD
J Virol; 2021 Nov; 95(23):e0088221. PubMed ID: 34549979
[TBL] [Abstract][Full Text] [Related]
15. Systematic HIV-1 promoter targeting with CRISPR/dCas9-VPR reveals optimal region for activation of the latent provirus.
Klinnert S; Chemnitzer A; Rusert P; Metzner KJ
J Gen Virol; 2022 Jun; 103(6):. PubMed ID: 35671066
[TBL] [Abstract][Full Text] [Related]
16. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.
Zhu W; Lei R; Le Duff Y; Li J; Guo F; Wainberg MA; Liang C
Retrovirology; 2015 Feb; 12():22. PubMed ID: 25808449
[TBL] [Abstract][Full Text] [Related]
17. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.
Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD
Retrovirology; 2018 Oct; 15(1):67. PubMed ID: 30286764
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
19. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
[TBL] [Abstract][Full Text] [Related]
20. A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.
Huang Z; Nair M
Sci Rep; 2017 Jul; 7(1):5955. PubMed ID: 28729655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
